US FDA to expand guidance on good reprint practices for off-label uses of devices, drugs
This article was originally published in Clinica
The US FDA is taking steps towards further clarifying how medical device and drug companies can disseminate to healthcare professionals medical literature that discusses the health benefits of unapproved uses of their approved products without contravening off-label promotion rules.
You may also be interested in...
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
New medicines under evaluation at the European Medicines Agency.